Dr Muhammad usman ghani

14/09/2025

Usman clinic bcg Chowk mumtaz abad multan

Dr Umair Ali fcps ( orthopedic) specialist in bone and joint disease Monday to Friday 6 c 9 pm .

Dr Ahmed khubaib DTCD pulmonologist specialist in lungs problems Monday to Saturday 6 se 9 pm .

Dr arslan mbbs general physician
Monday to Saturday 4 to 10 pm .

Dr usman ghani fcps med MRCP
Monday to Saturday 6 to 10 pm .

Contact for appointment
03282900057

For Whatsapp only
03036700056

30/08/2025

Clinic times has been extended .
You can find
Dr arslan (GP) from 4 to 10 pm Monday to Friday
Dr Ahmed ( pulmonologist)from 6 to 10 Monday to Friday
Dr Umar ( orthopaedic surgeon ) 6 to 9 pm Monday to Friday
Dr usman Monday to Friday 7 to 10 pm . Saturday 4 to 10 pm .

Sunday off .
Contact 03282900057 for appointment only .
Please make sure all consultations are by appointment only except GP or medical officer .
Thank you

08/08/2025

https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-delivers-weight-loss-average-273
Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity
Published Today August 7, 2025

04/08/2025

31/07/2025

INJ MOUNJARO FOR MASLD/MASH

Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis | New England Journal of Medicine

Metabolic dysfunction–associated steatohepatitis (MASH) is a progressive liver disease associated with liver-related complications and death. The efficacy and safety of tirzepatide, an agonist of t...

31/07/2025

Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis - Clinical Gastroenterology and Hepatology https://share.google/IoqxpD2XoJTuHKQko

Indication of RESMITEROM in MASLD/MASH .
In future , GLP-1 agonists will be given .

Metabolic dysfunction–associated steatotic liver disease affects 1 in 4 people in the United States and western Europe, with an important proportion developing metabolic dysfunction–associated steatohepatitis (MASH), the progressive subtype of metabolic dysfunction–associated steatotic live...

30/07/2025

Tirzepatide significantly improves insulin sensitivity within 12 weeks, indicating an early metabolic effect that is not solely attributable to weight loss link.springer.com/article/10.100…

Page unavailable The information you're looking for cannot be found, it may be temporarily unavailable or permanently removed. Try refreshing the page, or returning to our homepage. If the problem continues, please let us know.

27/07/2025

https://www.mdpi.com/2813-0618/4/3/14

Future of resmetirom and semaglutide in MAFLD / MASH .

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly encompassed under nonalcoholic fatty liver disease (NAFLD), is a growing global health burden associated with progression to cirrhosis and hepatocellular carcinoma. Resmetirom, a thyroid hormone receptor-β (THR...

06/07/2025

22 لاکھ مربع میل پر پھیلے ھوئے اسلام کو جب 10 محرم الحرام میں نچوڑا گیا تو صرف 72 جانثار نکلے!.

01/07/2025

https://journals.lww.com/hep/fulltext/2025/01000/resmetirom_therapy_for_metabolic.28.aspx

An abstract is unavailable.

24/06/2025

Once-weekly insulin could be ‘game changer’ for adults with type 2 diabetes https://share.google/tApv5VsV7oX7YnHQn
Once-weekly insulin could be ‘game changer’ for adults with type 2 diabetes

Key takeaways:
Insulin efsitora was noninferior to once-daily insulins in three randomized controlled trials.
Rates of level 2 and level 3 hypoglycemia were not higher with efsitora vs. once-daily insulins.
Published Yesterday 23 June 2025
2025
Scientific Sessions